Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.71 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.71 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.63 |
| ▸ | AKT1 | P31749 | 1/20 | 0.60 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.59 |
| ▸ | CHRNG | P07510 | 1/20 | 0.59 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.59 |
| ▸ | CHRND | Q07001 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6581924 | 0.99 | CHRNB4 (0.69) | CHRNB4CHRNA3CHRNB2CHRNA4AKT1 | |
| SCHEMBL2441396 | 0.90 | CHRNB2 (0.68) | CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL7455797 | 0.88 | CHRNB2 (0.67) | CHRNB2CHRNA4 | |
| SCHEMBL3223507 | 0.83 | CHRNA3 (0.71) | CHRNB4CHRNA3CHRNB2CHRNA4AKT1 | |
| SCHEMBL905216 | 0.83 | CHRNA3 (0.71) | CHRNB4CHRNA3CHRNB2CHRNA4AKT1 | |
| SCHEMBL7409154 | 0.83 | CHRNB4 (0.71) | CHRNB4CHRNA3CHRNB2CHRNA4AKT1 | |
| SCHEMBL14068193 | 0.83 | CHRNB4 (0.71) | CHRNB4CHRNA3CHRNB2CHRNA4AKT1 | |
| SCHEMBL905203 | 0.83 | CHRNA3 (0.71) | CHRNB4CHRNA3CHRNB2CHRNA4AKT1 | |
| Hydrochloric Acid SCHEMBL7373497 | 0.82 | CHRNA3 (0.69) | CHRNB4CHRNA3CHRNB2CHRNA4AKT1 | |
| Hydrochloric Acid SCHEMBL7839142 | 0.82 | CHRNA3 (0.69) | CHRNB4CHRNA3CHRNB2CHRNA4AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5948793-A | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release | ABBOTT LABORATORIES (US) | 1999-09-07 | — | — | US | claimed |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-04-05 | — | — | US | disclosed |
| US-9782404-B2 | Methods of treating disease-induced ataxia and non-ataxic imbalance | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-10-10 | — | — | US | disclosed |
| US-9463190-B2 | Methods of treating disease-induced ataxia and non-ataxic imbalance | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140371208-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA | 2014-12-18 | — | — | US | disclosed |
| US-20110237597-A1 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | UNIVERSITY OF SOUTH FLORIDA | 2011-09-29 | — | — | US | disclosed |
| EP-2300012-A2 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | University of South Florida (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20110059905-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA | 2011-03-10 | — | — | US | disclosed |
| EP-2271344-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | University of South Florida (US) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009146031-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009143019-A2 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-11-26 | — | — | WO | disclosed |
| EP-0934308-B1 | 3-PYRIDYLOXYMETHYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LAB (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6437138-B1 | 5-BROMO-6-CHLORO-3-(2-(S)-AZETIDINYL OR PYRROLIDINYL-METHOXY) PYRIDINE INTERMEDIATES FOR THE 5-SUBSTITUTED COMPOUNDS WHICH ARE POTENT LIGANDS AT NEURONAL NICOTINIC CHOLINERGIC CHANNEL RECEPTORS, NEUROTRANSMITTER CONTROLLING AGENTS | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| US-6127386-A | STIMULANTS, NEUROTRANSMITTERS, CHOLINERGIC AGENTS | ABBOTT LABORATORIES (US) | 2000-10-03 | — | — | US | disclosed |
| US-5948793-A | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release | ABBOTT LABORATORIES (US) | 1999-09-07 | — | — | US | disclosed |
| US-5629325-A | TREATMENT OF NERVOUS SYSTEM DISORDERS; NEURONAL NICOTINIC CHOLINERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371208-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CHRNB4 10/4885CHRNA3 6/4885CHRNB2 9/4885 |
| US-20110059905-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CHRNB4 10/4885CHRNA3 6/4885CHRNB2 9/4885 |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CHRNB4 10/4885CHRNA3 6/4885CHRNB2 9/4885 |
| US-20110237597-A1 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ACHE, CHRNA6, CHRNB2 | CHRNB4 7/4885CHRNA3 13/4885CHRNB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.